德視佳(01846.HK)擬收購優質視力矯正服務業務 涉足倫敦屈光手術及老花眼手術高端市場
格隆匯1月20日丨德視佳(01846.HK)公吿，於2022年1月20日，公司、EuroEyesUK、合法擁有人、合夥人及賣方LVC Partnership訂立購股協議，據此，EuroEyesUK同意收購，及合法擁有人同意出售標的公司London Vision Clinic Partners Limited全部股份。
根據購股協議所載條款及條件，買賣銷售股份的代價應以下列方式償付：(a)完成現金代價；(b)完成代價股份；(c)或有現金代價；及(d)盈利支付代價，並可能進行代價調整。
於完成後，賣方(或根據購股協議的條款及條件獲提名的合夥人)將持有經配發及發行完成代價股份擴大後本公司已發行股本約1.20%。完成代價股份將按每股完成代價股份8.323港元的發行價發行，發行價較1月20日收市價每股9.36港元折讓約11.1%。
標的公司為一間於英格蘭和威爾士註冊成立的有限公司，及主要提供優質的視力矯正服務，包括PRK、LASIK、SMILE、後房型人工晶體(ICL)植入術以及屈光性白內障手術等。標的公司憑藉其進行細緻而全面的測試及診斷能力，以及其在向專家外科醫生提供培訓及處理複雜病例方面的專業知識而享譽全球的聲譽，一直是英國市場的領導者及價格領先者。標的公司乃英國為治療老花眼提供激光視力矯正方案的領先者之一。
London Vision Clinic Training是一家於英格蘭和威爾士註冊成立的公司及標的公司的全資附屬公司。隨着London Vision Clinic Training新近於2021年8月25日註冊成立，其將展開收購後業務並將主要從事提供屈光手術相關的線上及線下培訓。Reinstein教授將是London Vision Clinic Training的主講人和培訓師之一。
集團一直積極尋求市場機會以擴大其服務網絡，從而提升協同效應併為集團眼科服務帶來裨益。董事認為收購事項是集團涉足倫敦屈光手術及老花眼手術高端市場及擴展其業務的良機。
於收購事項完成後，Reinstein教授亦將擔任集團國際醫療顧問委員會的醫療總監。考慮到Reinstein教授的專業知識，董事會認為此舉將令集團能夠接觸到更多早期可能患有老花眼的患者。董事認為，收購事項將支持集團收入及利潤的長期增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
